ICAD (ICAD) Stock Price
ICAD Price
Revenue at ICAD has contracted by 0.0% per year over the past 19 years to 19.61 M USD. For ICAD, the net margin of -28.6% is up versus -59.3% a few years ago. The consensus 12-month price target for ICAD is 3.57 USD, about 7.8% below where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.
ICAD stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of ICAD over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how ICAD stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing ICAD's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | ICAD Price |
|---|
ICAD Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
ICAD Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28.00 | 33.00 | 43.00 | 41.00 | 26.00 | 28.00 | 25.00 | 31.00 | 29.00 | 33.00 | 27.00 | 17.00 | 19.00 | 19.00 | 22.00 | 27.00 |
| – | 17.86 | 30.30 | -4.65 | -36.59 | 7.69 | -10.71 | 24.00 | -6.45 | 13.79 | -18.18 | -37.04 | 11.76 | – | 15.79 | 22.73 |
| 71.43 | 69.70 | 72.09 | 70.73 | 69.23 | 64.29 | 76.00 | 77.42 | 72.41 | 72.73 | 70.37 | 82.35 | 84.21 | 84.21 | 84.21 | 84.21 |
| 20.00 | 23.00 | 31.00 | 29.00 | 18.00 | 18.00 | 19.00 | 24.00 | 21.00 | 24.00 | 19.00 | 14.00 | 16.00 | 16.00 | 18.53 | 22.74 |
| -5.00 | -1.00 | – | -30.00 | -9.00 | -14.00 | -8.00 | -6.00 | -9.00 | -11.00 | -13.00 | -7.00 | -6.00 | -7.00 | -8.00 | -10.00 |
| -17.86 | -3.03 | – | -73.17 | -34.62 | -50.00 | -32.00 | -19.35 | -31.03 | -33.33 | -48.15 | -41.18 | -31.58 | -36.84 | -36.36 | -37.04 |
| -9.00 | -7.00 | -1.00 | -32.00 | -10.00 | -14.00 | -9.00 | -13.00 | -17.00 | -11.00 | -13.00 | -4.00 | -5.00 | -4.00 | -3.00 | – |
| -75.68 | -22.22 | -85.71 | 3,100.00 | -68.75 | 40.00 | -35.71 | 44.44 | 30.77 | -35.29 | 18.18 | -69.23 | 25.00 | -20.00 | -25.00 | – |
| 10.81 | 10.86 | 15.54 | 15.73 | 16.21 | 16.50 | 16.77 | 19.32 | 23.07 | 25.13 | 25.26 | 26.32 | 26.35 | 26.35 | 26.35 | 26.35 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales ICAD generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue ICAD retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare ICAD's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares ICAD has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against ICAD's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
ICAD stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
ICAD Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
ICAD business model & stock analysis
ICAD SWOT Analysis
Strengths
ICAD Inc has a strong reputation in the industry and is known for its innovative products.
The company has a dedicated and skilled workforce, which contributes to its success.
ICAD Inc has a wide range of intellectual property rights and patents, providing a competitive advantage.
Weaknesses
ICAD Inc is heavily dependent on a few key clients, which poses a risk to its revenue stability.
The company has limited geographic reach, which limits its potential market and growth opportunities.
ICAD Inc faces challenges in terms of maintaining cost competitiveness compared to its larger competitors.
Opportunities
ICAD Inc can explore strategic partnerships or acquisitions to expand its market presence.
The growing demand for advanced technology solutions provides opportunities for ICAD Inc to develop new products.
The company can leverage its technology expertise to enter new industries and diversify its revenue streams.
Threats
ICAD Inc faces intense competition from both established players and emerging startups in the industry.
Economic downturns or market fluctuations can impact the company's sales and profitability.
Changes in regulations or policies may affect ICAD Inc's ability to operate or disrupt its supply chain.
ICAD Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
ICAD Segments
ICAD Revenue by Segment (1/3)
3 Years
5 Years
Max
Details
ICAD Revenue by Segment (2/3)
3 Years
5 Years
Max
Details
ICAD Revenue by Segment (3/3)
3 Years
5 Years
Max
Details
ICAD Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
ICAD historical P/E ratio, EBIT multiple, and P/S ratio
ICAD annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
ICAD shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
ICAD stock splits
Current ICAD forecasts and price targets in September 2026
Analyst Price Targets 2026ICAD Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 4/17/2025 | Downgrade | BuyHold | – | |
| 7/19/2023 | Maintained | Buy | – | |
| 4/13/2023 | Maintained | Outperform | – | |
| 4/4/2023 | Maintained | Outperform | 62 | |
| 3/29/2023 | Maintained | Buy | – | |
| 3/29/2023 | Maintained | Buy | 52 | |
| 9/1/2022 | Maintained | Market Outperform | – | |
| 8/11/2022 | Maintained | Buy | – | |
| 6/24/2022 | Maintained | Buy | 52 | |
| 1/18/2022 | Downgrade | BuyNeutral | 30 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
ICAD Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 5/11/2026 | -0.03USD | - | 3.16 MUSD | - | 2026 Q1 |
| 3/17/2026 | -0.05USD | - | 5.50 MUSD | - | 2025 Q4 |
| 8/11/2025 | -0.06USD | - | 4.85 MUSD | - | 2025 Q2 |
| 11/13/2024 | -0.09USD | - | 4.61 MUSD | - | 2024 Q3 |
| 5/13/2024 | -0.05USD | - | 4.39 MUSD | - | 2024 Q1 |
| 3/26/2024 | -0.05USD | - | 4.39 MUSD | - | 2023 Q4 |
| 11/8/2023 | -0.11USD | - | 8.20 MUSD | - | 2023 Q3 |
| 8/8/2023 | -0.11USD | - | 9.85 MUSD | - | 2023 Q2 |
| 11/10/2022 | -0.13USD | - | 8.19 MUSD | - | 2022 Q3 |
EESG©
Eulerpool ESG Scorecard© for the ICAD stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
ICAD shareholder structure
| % | Name |
|---|---|
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% | |
0.00000% |
ICAD Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
16.30% | SEC ↗ | |
9.49% | SEC ↗ | |
7.60% | SEC ↗ | |
6.80% | SEC ↗ | |
6.80% | SEC ↗ | |
6.60% | SEC ↗ | |
6.60% | SEC ↗ | |
6.50% | SEC ↗ | |
6.50% | SEC ↗ | |
6.50% | SEC ↗ |
ICAD Executives and Management Board
10 members · avg. age 63 · 30 % women
Ms. Dana Brown (60)
Executive Chairman of the Board, President, Chief Executive Officer · since 2022
497,702.00 USD
Management
Mr. Jonathan Go
Chief Technology Officer
Mr. Eric Lonnqvist
Chief Financial Officer
Mr. Mark Koeniguer
Chief Commercial Officer
Mr. John Nesbett
Investor Relations · since 2025
Board of Directors
Mr. Andrew Sassine (60)
Independent Director
Dr. Susan Wood (62)
Independent Director
Dr. Rakesh Patel (52)
Independent Director
Mr. Michael Doyle (66)
Independent Director
Dr. Hedvig Hricak (78)
Independent Director
ICAD Supply Chain
ICAD Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.80 | 0.90 | 0.85 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.65 | -0.69 | -0.31 | ||
| 2 | 0.88 | 0.38 | -0.15 | ||
| 3 | -0.08 | -0.33 | -0.09 | ||
| 4 | 0.81 | 0.17 | 0.08 | ||
| 5 | 0.83 | 0.67 | 0.08 |
Frequently asked questions about ICAD
ICAD Inc's business model primarily focuses on providing innovative medical solutions to enhance cancer detection and therapy planning. As a leading provider of advanced imaging and radiation therapy technologies, ICAD aims to deliver state-of-the-art solutions that enable healthcare professionals to accurately diagnose and treat patients. Their expertise lies in developing and commercializing computer-aided detection (CAD) and workflow solutions for medical imaging in specialties such as breast, lung, and colon health. With a mission to improve patient outcomes and healthcare efficiency, ICAD Inc strives to revolutionize cancer care through their cutting-edge technologies.
ICAD Inc is primarily active in the healthcare and technology industries.
The main competitors of ICAD Inc in the market include companies like Varian Medical Systems, Elekta AB, and Accuray Incorporated.
ICAD Inc is a renowned company that specializes in advanced image analysis and cancer detection technologies. With a rich history spanning several decades, ICAD Inc was founded in 1984 as a research and development firm focusing on computer-aided detection (CAD) tools for mammography. Over the years, the company expanded its portfolio, offering innovative solutions for various cancer types, including lung, colon, and prostate. With a commitment to improving patient outcomes, ICAD Inc remains at the forefront of cutting-edge medical advancements. Leveraging its expertise in artificial intelligence and machine learning, ICAD Inc continues to deliver state-of-the-art solutions for early cancer detection, contributing to the advancement of medical diagnostics.
ICAD Inc has achieved several significant milestones over the years. Some of these include the development of innovative and leading-edge solutions for advanced imaging in the healthcare industry. The company has also successfully launched its renowned ProFound AI platform, which provides invaluable assistance to radiologists in the early detection of breast cancer. Furthermore, ICAD Inc has consistently focused on expanding its global presence by forging strategic partnerships and collaborations with industry leaders. With a commitment to continuous research and development, ICAD Inc continues to revolutionize the field of medical imaging, ensuring improved patient outcomes and enhanced clinical workflows.
ICAD Inc is primarily present in the United States, with headquarters located in Nashua, New Hampshire. As a leading provider of advanced image analysis technology solutions for the healthcare industry, ICAD Inc serves customers across the United States and also has a strong presence in Europe, Asia, and other regions around the globe. With its innovative solutions and commitment to improving patient outcomes, ICAD Inc continues to expand its reach in healthcare markets worldwide.
ICAD Inc represents values of innovation, collaboration, and dedication to advanced medical imaging technology. With a strong corporate philosophy focused on enhancing patient care and improving clinical outcomes, ICAD Inc continually develops cutting-edge solutions for early cancer detection and radiation therapy. By combining their expertise in artificial intelligence and image analysis, ICAD Inc enables healthcare professionals to make more accurate diagnoses and tailor personalized treatment plans. With a commitment to continuous improvement and providing superior healthcare solutions, ICAD Inc has established itself as a trusted leader in the industry.
Analysts currently set an average price target of 3.57 USD for the ICAD stock (median: 3.57 USD), implying -7.8 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the ICAD stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect ICAD to generate revenue of 22.33 M USD and earnings per share of -0.12 USD.
Converted at the current exchange rate, the ICAD share trades at 3.33 EUR (3.87 USD).
The ICAD share (ICAD) is listed on 1 stock exchanges, including: NASDAQ (ICAD).
ICAD Inc is a US-based company that has been operating in the field of medical imaging since 1984. The company's business model focuses on the development and manufacturing of advanced imaging products. ICAD offers two main product lines: iCADx and ProFound AI. iCADx is a specialized group of diagnostic products used in image analysis in radiology and brachytherapy. ProFound AI is a groundbreaking software platform specifically designed for the interpretation of digital breast tomosynthesis (DBT). The two product lines from ICAD allow doctors to obtain more accurate and faster diagnostic results. The iCADx brand offers a range of products for the treatment of breast, prostate, lung, bone, and other types of cancer. The range also includes equipment for brachytherapy, a form of radiation therapy where a radiation source is directly inserted into the body. ProFound AI is an artificial intelligence (AI)-based software platform specifically designed for breast imaging. The system uses state-of-the-art algorithms and image analysis functions to assist the doctor in the early detection and diagnosis of breast cancer. In addition, ICAD also offers professional services such as training, customer support, and technical support. These services are aimed at ensuring that the products are used optimally and achieve the highest quality of imaging and diagnosis. ICAD also operates in the research and development field. The company continuously invests in research and development to improve and further develop its products, in order to provide medical users with the best possible diagnostics. The company also actively collaborates with leading medical institutions, research organizations, and other companies to drive collaborative projects and innovation in the field of medical imaging. In conclusion, it can be said that ICAD's business model is based on state-of-the-art medical imaging technology that improves diagnosis in medical practice. ICAD aims to drive further growth and expansion of the company by constantly improving its technologies and introducing innovative products to the market.
The expected revenue of ICAD is 22.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ICAD is -3.03 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ICAD is currently -33.65. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ICAD stock.
The price-to-sales ratio (P/S) of ICAD is currently 4.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ICAD stock.
The Eulerpool Quality Score for ICAD is 1/10.
The ISIN of ICAD is US44934S2068. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ICAD is A1J20J. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ICAD is ICAD. The ticker symbol is used to trade ICAD shares on the stock exchange.
ICAD paid dividends every year for the past 0 years.
ICAD is assigned to the 'Health' sector.
The dividends of ICAD are distributed in USD.
ICAD stock
ICAD Peer Group
ICAD Ticker
ICAD FIGI
All fundamentals and in-depth analysis of ICAD
Our stock analysis for ICAD stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ICAD. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.